A 10-Year, Post-marketing, Observational Study to Assess Long Term Safety of HUMIRA® (Adalimumab) in Adult Patients With Chronic Plaque Psoriasis (PS) (ESPRIT) First published 13/08/2019 Last updated 28/01/2026 EU PAS number:EUPAS30560 Study Finalised